Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
(CSE:
MBIO
)
0.0350
UNCHANGED
Streaming Delayed Price
Updated: 10:49 AM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
48,611
Open
0.0300
Bid (Size)
0.0300 (6,000)
Ask (Size)
0.0350 (114,000)
Prev. Close
0.0350
Today's Range
0.0300 - 0.0350
52wk Range
0.0150 - 0.0800
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
August 19, 2024
Via
ACCESSWIRE
MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
August 01, 2024
Via
ACCESSWIRE
Performance
YTD
+75.00%
+75.00%
1 Month
N/A
N/A
3 Month
-22.22%
-22.22%
6 Month
-30.00%
-30.00%
1 Year
-22.22%
-22.22%
More News
Read More
Mindbio Therapeutics CEO Issues Letter To Shareholders
July 08, 2024
Via
ACCESSWIRE
MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
June 20, 2024
Via
ACCESSWIRE
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
June 12, 2024
Via
ACCESSWIRE
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
April 30, 2024
Via
ACCESSWIRE
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
April 22, 2024
Via
ACCESSWIRE
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
May 14, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
May 14, 2024
Via
ACCESSWIRE
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
May 02, 2024
Via
ACCESSWIRE
MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
May 01, 2024
Via
ACCESSWIRE
LSD Microdosing For PMS? After Confirming Antidepressant Effects, Clinical Trials Will Assess If It Addresses Mood Issues
April 30, 2024
Via
Benzinga
Lender Requests to Convert Loan to MindBio Shares
April 16, 2024
Via
ACCESSWIRE
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
March 20, 2024
Via
ACCESSWIRE
MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
March 04, 2024
Via
ACCESSWIRE
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
February 25, 2024
Via
ACCESSWIRE
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
February 13, 2024
Via
ACCESSWIRE
MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
January 29, 2024
Via
ACCESSWIRE
MindBio Therapeutics CEO Provides End of Year Video Update on Phase 2 Clinical Trials
December 20, 2023
Via
ACCESSWIRE
MindBio Therapeutics Team Members Honoured with Industry Leading Awards
November 21, 2023
Via
ACCESSWIRE
MindBio Therapeutics CEO Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer Patients
October 31, 2023
Via
ACCESSWIRE
MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients
October 28, 2023
Via
ACCESSWIRE
Mindbio Therapeutics Nominated for Company of the Year in Industry Awards
October 26, 2023
Via
ACCESSWIRE
MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001
October 24, 2023
Via
ACCESSWIRE
Tenth Patient With Depression Starts Dosing MB22001 in Take Home Microdosing Trials
October 05, 2023
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.